This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This SLAMF7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 58-85 amino acids from the Central region of human SLAMF7.
SLAMF7
Reaktivität: Human
WB
Wirt: Maus
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
RGD1560190 antikoerper, SLAMF7 antikoerper, slaf7 antikoerper, 19A antikoerper, CD319 antikoerper, CRACC antikoerper, CS1 antikoerper, 19A24 antikoerper, 4930560D03Rik antikoerper, SLAM family member 7 antikoerper, Slamf7 antikoerper, SLAMF7 antikoerper, slaf7 antikoerper
Hintergrund
SLAMF7 contains one Ig-like C2-type (immunoglobulin-like) domain. Isoform 1 mediates NK cell activation through a SAP-independent extracellular signal-regulated ERK-mediated pathway. It may play a role in lymphocyte adhesion. Isoform 3 does not mediate any activation. SAP can bind the cytoplasmic tail of isoform 1 when phosphorylated in the presence of Fyn (in vitro). SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. The isoform 3 is expressed at much lower level than isoform 1. There are three named isoforms.